Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair... see more

TSXV:RP - Post Discussion

View:
Post by Ingiboy on Jan 11, 2021 2:05pm

Two Months

Today makrs 2 months since the announcement of a Binding Term Sheet with Mainpointe

Twitter Dec. 7th : All is going smoothly in the last stages of getting the RepliCel-MainPointe deal to signature. Some last minute due diligence items being cleared up. #nohickups

How many "last minutes" are we talking about ? This is 4 days later. Do these guys have any sense of how they have shite on any momentum of the share price. Back trading at $.215.
Comment by MetzGER on Jan 11, 2021 5:24pm
MainPointe is the Company of Andrew Schuttes Brother and his father. They WILL 100% fix this deal. The Schuttes have a Big Plan for RepliCel. they know that replicel has the Upper Hand in the Shiseido relationship. they know that the Dermal Injector Will Be a huge vehicle Leading to a Big Future. I am sure that After the Deal will Happen you won’t Be Able to Buy Replicel at a Share Price of 0.21 ...more  
Comment by Ingiboy on Jan 11, 2021 6:05pm
Metzger I love your optimism regarding the future share price.  i assume you have made these predictions based on some complicated algorythm.  As I have said before at this point $1.00 is a lofty goal. Hopefully when we hear the details of the plan to commercialize the Dermal Injector we will hear some actual figures and projections that will enable us to calculate it's impact on ...more  
Comment by Genie29j on Jan 11, 2021 6:45pm
Sorry Ingiboy, but you have disconnect if you think the valuation will only be $1.  $1 means you think the decive will only be work about $10M and everything else will fail. Simply wrong. 
Comment by Ingiboy on Jan 11, 2021 7:35pm
 Oh Genie29J we can all dream of the future price of Replicel.  I too would certainly love to see $5.00, $10.00 or even $30.00.  You may have misread my post.  All I am saying is that let's get to a $1.00 before we think of much loftier share prices.   The question in the short term is when we see this long awaited announcement of this deal being signed where will the ...more  
Comment by Genie29j on Jan 12, 2021 12:14am
Ahh, my bad. Yes, agree...first things first. Let's get to a $1 i do think if it gets to $1 (or any larger substantial higher amounts) there will be significant profit takers. Pending on the news, it could be a rollercoaster of a ride with the ebbs and flows of the price 
Comment by Genie29j on Jan 11, 2021 6:43pm
I like the way you think on this Metz
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities